publication date: May. 15, 2015

AACR: 21st Century Cures a “Model for An Open and Honest Conversation” 



Almost one year ago (on April 30, 2014), House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), along with Oversight and Investigations Subcommittee Ranking Member Diana DeGette (D-Colo.) announced the launch of 21st Century Cures, an initiative aimed at accelerating the pace of cures and medical breakthroughs in the United States by ensuring that our laws are keeping pace with innovation.

Chairman Upton said at the time, “For the first time ever, we in Congress are going to take a comprehensive look at what steps we can take to accelerate the pace of cures in America. We are looking at the full arc of this process—from the discovery of clues in basic science, to streamlining the drug and device development process, to unleashing the power of digital medicine and social media at the treatment delivery phase.”

During the past year, the Committee has held eight hearings, issued a number of white papers, and hosted more than two-dozen roundtables across the country to generate ideas for this initiative. The initial discussion draft, which was initially released in January, was the product of months of dialogue between members of Congress, patients, innovators, researchers, providers, consumers, and regulators. Yesterday, a House Energy and Commerce Subcommittee marked-up a revised 21st Century Cures Act and unanimously approved the measure. A full Committee markup of the bill is planned for next week.

During this open and inclusive process to develop … Continue reading 41-19 Guest Editorial: AACR: 21st Century Cures a “Model for An Open and Honest Conversation”

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.